EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

EXTX fair value: what the stock is really worth

As of Oct 7, 2026: fair value of EXTX NOK 0.21, price NOK 0.48, upside -56.3%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · NO · ISIN NO0010852213

E Thin data Sep 27, 2026

EXTX

EXTX · OL

Weakest SetupStrongly overvalued and low quality.

Fair value kr 0.2100 · Strongly overvalued (−56.3%)
Quality 37/100
Weak Growth
Negative free cash flow
Trails peers (1/5)
Narrow moat 3/100
Thin data
Watch EXTX for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 24.80 kr 0.4800 Fair Value kr 0.2100 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range kr 0.4800 – kr 24.80 · fair‑value band kr 0.1400 – kr 0.2700 · the kr 0.4800 price screens above the kr 0.2100 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow EXTX in your weekly email

Every Wednesday you see whether EXTX is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway.

Show more

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company's ACT platform is under Phase 2 clinical trial for the treatment of pancreatic disease; Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. It has a collaboration with GE Healthcare. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.

Stock analysis

EXTX (EXTX) currently trades at kr 0.4800, while our model-based Fair Value estimate is kr 0.2100, 56.3% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 0.1400 (bear) to kr 0.2700 (bull), the price of kr 0.4800 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

EXTX reported revenue of 0 NOK in FY2025 versus 0 NOK in FY2021. Reported net income was −87.0M NOK in FY2025.

Key figures

Market cap 88.1M NOK (≈ $9.2M) · EPS (TTM) kr −0.9300 · Return on equity −113% · Return on assets (EBIT) −67.8% · Operating margin −199,799% · Revenue (TTM) 78.0K NOK · Free cash flow −72.3M NOK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 82% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −56%, EXTX screens richer than that median.

Fair Value models

Bear kr 0.1400 Fair Value kr 0.2100 Bull kr 0.2700
Price kr 0.4800 · Upside -56.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.1400 kr 0.1800 kr 0.2800 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.1400 kr 0.1800 kr 0.2800 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

Of which business quality 37 · Market factors (momentum, volatility) 17

Profitability 0
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 18
Earnings quality: real cash, not paper profit
Fin. Strength 66
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 5
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EXTX screens overvalued: fair value 56% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare EXTX with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 590 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −56.3% · Below median
Profitability
Return on assets −51.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.30× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73% vs EXTX
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10% vs EXTX
CSL Limited CSL A$175.35 A$192.89 +10% vs EXTX
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10% vs EXTX
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10% vs EXTX
argenx SE ARGX $959.49 $918.60 −4% vs EXTX
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15% vs EXTX
BeOne Medicines AG ONC $360.85 $280.94 −22% vs EXTX
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58% vs EXTX
Royalty Pharma plc RPRX $58.21 $19.01 −67% vs EXTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

EXTX · Fair Value
kr 0.2100 −56%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "EXTX Fair Value". https://www.fairvalue-calculator.com/stock/EXTX

Frequently asked questions

Is EXTX overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of kr 0.2100 versus a price of kr 0.4800, about −56% upside (overvalued).
What is the fair value of EXTX?
Our model-based fair value for EXTX is kr 0.2100 (as of Sep 27, 2026), built from audited fundamentals. The current price: kr 0.4800.
What is the quality score of EXTX?
EXTX has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EXTX?
Our model-based price target is the fair value of kr 0.2100 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario kr 0.1400, optimistic scenario kr 0.2700. It is a calculation from audited fundamentals, not an analyst target.
What is the EXTX stock forecast for 2026?
Our models put fair value at kr 0.2100, about −56% upside versus a price of kr 0.4800 (overvalued). Cautious scenario kr 0.1400, optimistic scenario kr 0.2700. The calculation is refreshed regularly with new filings.
What is the revenue of EXTX?
EXTX reported trailing-twelve-month revenue of about 78.0K NOK (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of EXTX?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EXTX it is kr 0.2100 per share (as of Sep 27, 2026), against a price of kr 0.4800. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is EXTX stock overvalued or undervalued in 2026?
As of Sep 27, 2026, EXTX trades above its calculated fair value: price kr 0.4800, fair value kr 0.2100, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EXTX?
No. The price is what the market pays today (kr 0.4800); the fair value is what the company's own numbers justify (kr 0.2100). For EXTX the two are kr 0.2700 per share apart. That gap is exactly why we show both numbers side by side.
How much is EXTX worth?
The market values EXTX at about 88.1M NOK (market capitalisation, as of Sep 27, 2026). Per share that is kr 0.4800; our models calculate a fair value of kr 0.2100 per share.
What do the bullish and bearish scenarios say about EXTX?
Our models span a range for EXTX: cautious scenario kr 0.1400, base kr 0.2100, optimistic kr 0.2700 per share (as of Sep 27, 2026, price kr 0.4800). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EXTX?
Balance-sheet figures for EXTX (as of Sep 27, 2026): return on equity −113.5%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is EXTX from its 52-week high?
EXTX trades at kr 0.4800, about 82% below its 52-week high of kr 2.70 and at the low of kr 0.4800 (as of Oct 7, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.2100 is for.
Which stocks are comparable to EXTX?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EXTX stock attractive at the current price?
The data as of Sep 27, 2026: price kr 0.4800, calculated fair value kr 0.2100 (−56%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EXTX calculated?
We run EXTX through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.2100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.3 % above its aggregate fair value. EXTX itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EXTX?
The closing price on Oct 7, 2026 was kr 0.4800. Our model-based fair value is kr 0.2100, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EXTX right now?
The price sits above even our optimistic bull case (kr 0.2700). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.1400 to kr 0.2700) leaves room in how you read the outcome.

Key figures of EXTX

How large is the market capitalisation of EXTX?
The market capitalisation of EXTX is 88.1M NOK (≈ $9.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of EXTX?
Earnings per share at EXTX are kr −0.9300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of EXTX?
The return on equity (ROE) of EXTX is −113% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EXTX?
On an EBIT basis the return on assets of EXTX is −67.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EXTX?
The operating margin of EXTX is −199,799% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does EXTX generate?
The free cash flow of EXTX is −72.3M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch EXTX in the live analysis

One click puts EXTX on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.